HK Stock Market Move | KEYMED BIO-B (02162) dropped by more than 10% once, stock price is currently in seven consecutive declines, rumors of the company's competitor offering a lower price for medical insurance renewal exceeded expectations.

KEYMED BIO-B (02162) fell more than 10%, with the stock price showing a seven-day consecutive decline. As of press time, it fell by 6.38% to 30.8 Hong Kong dollars, with a turnover of 95.3227 million Hong Kong dollars. On the news front, there have been rumors circulating in the market recently about a significant price reduction for the renewal of the medical insurance for Dupilumab (Dupixent). The news states that the medical insurance payment price for this drug in 2024 will be reduced from 2780 yuan per dose to a potential 1508 yuan per dose after renewal. However, this news has not been officially confirmed. It is reported that in September of this year, Canoviya announced the domestic market approval of its core product, Dupilumab (Consistency), becoming the second drug globally targeting the IL-4R receptor point after Sanofi's star product Dupilumab. It is worth noting that the price of Dupilumab has been on a downward trend since its introduction to the market. When it was first launched domestically in July 2020, the 300mg/dose specification of Dupilumab was priced as high as 6666 yuan per dose; after being included in the medical insurance catalog in March 2021, the price for the same specification was reduced to 3160 yuan per dose; and during the medical insurance renewal in January last year, the price for the same specification of the drug further decreased to 2780 yuan.